Welcome to the Oyster Point Pharma Multimedia page.
Below, please find our downloadable assets and embed links for use at your discretion.
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.
Tyrvaya® (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.
Please click here for full Prescribing Information.
© 2022 Oyster Point Pharma, Inc. Oyster Point®, the Oyster Point logo, Tyrvaya®, and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc. in the United States and certain jurisdictions. All rights reserved.
OP-TYR-001378 4/22